JP2007509063A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007509063A5 JP2007509063A5 JP2006535420A JP2006535420A JP2007509063A5 JP 2007509063 A5 JP2007509063 A5 JP 2007509063A5 JP 2006535420 A JP2006535420 A JP 2006535420A JP 2006535420 A JP2006535420 A JP 2006535420A JP 2007509063 A5 JP2007509063 A5 JP 2007509063A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell
- population
- vaccine
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000001744 T-lymphocyte Anatomy 0.000 claims 12
- 239000000427 antigen Substances 0.000 claims 8
- 102000036639 antigens Human genes 0.000 claims 8
- 108091007433 antigens Proteins 0.000 claims 8
- 238000000034 method Methods 0.000 claims 6
- 229940030156 cell vaccine Drugs 0.000 claims 5
- 229960005486 vaccine Drugs 0.000 claims 4
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 claims 2
- 102000047918 Myelin Basic Human genes 0.000 claims 2
- 101710107068 Myelin basic protein Proteins 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 239000003226 mitogen Substances 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 2
- 108010062580 Concanavalin A Proteins 0.000 claims 1
- 102000003886 Glycoproteins Human genes 0.000 claims 1
- 108090000288 Glycoproteins Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 102000055324 Myelin Proteolipid Human genes 0.000 claims 1
- 108700021862 Myelin Proteolipid Proteins 0.000 claims 1
- 102000002233 Myelin-Oligodendrocyte Glycoprotein Human genes 0.000 claims 1
- 108010000123 Myelin-Oligodendrocyte Glycoprotein Proteins 0.000 claims 1
- 108010033737 Pokeweed Mitogens Proteins 0.000 claims 1
- 102000016202 Proteolipids Human genes 0.000 claims 1
- 108010010974 Proteolipids Proteins 0.000 claims 1
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000004248 oligodendroglia Anatomy 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51221203P | 2003-10-17 | 2003-10-17 | |
| PCT/US2004/034448 WO2005037309A1 (en) | 2003-10-17 | 2004-10-18 | A method for increasing cd8+ cytotoxic t cell reponses and for treating multiple sclerosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007509063A JP2007509063A (ja) | 2007-04-12 |
| JP2007509063A5 true JP2007509063A5 (enExample) | 2007-11-29 |
Family
ID=34465326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006535420A Pending JP2007509063A (ja) | 2003-10-17 | 2004-10-18 | Ｃｄ８＋細胞傷害性ｔ細胞応答を増大させる方法、および多発性硬化症を処置するための方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20080107664A1 (enExample) |
| EP (1) | EP1677821B1 (enExample) |
| JP (1) | JP2007509063A (enExample) |
| CN (1) | CN1893971A (enExample) |
| AU (1) | AU2004281817B2 (enExample) |
| BR (1) | BRPI0415519A (enExample) |
| CA (1) | CA2542668C (enExample) |
| IL (1) | IL174935A (enExample) |
| NZ (1) | NZ546552A (enExample) |
| WO (1) | WO2005037309A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1677821B1 (en) * | 2003-10-17 | 2013-02-27 | Baylor College Of Medicine | A method for increasing cd8+ cytotoxic t cell reponses and for treating multiple sclerosis |
| AU2007247869B2 (en) * | 2006-05-05 | 2013-11-21 | Opexa Therapeutics | T-cell vaccine |
| EP2050814A1 (en) * | 2007-10-17 | 2009-04-22 | Txcell | Compositions for treating multiple sclerosis |
| WO2011060329A1 (en) * | 2009-11-14 | 2011-05-19 | Kuang-Yuh Chyu | Immunomodulatory methods and systems for treatment and/or prevention of atherosclerosis |
| RU2435556C1 (ru) * | 2010-04-23 | 2011-12-10 | Владимир Васильевич Лантух | Способ лечения дистрофических заболеваний заднего полюса глаза |
| WO2013063713A1 (zh) * | 2011-10-31 | 2013-05-10 | 鑫品生医科技股份有限公司 | 诱发产生综合免疫细胞的方法 |
| CN105085616A (zh) * | 2014-05-23 | 2015-11-25 | 上海市普陀区中心医院 | 一种氨基酸序列及其应用 |
| CN105085615A (zh) * | 2014-05-23 | 2015-11-25 | 上海市普陀区中心医院 | 一种多肽序列及其应用 |
| US20190350981A1 (en) * | 2017-01-20 | 2019-11-21 | Atara Biotherapeutics, Inc. | Methods of treating multiple sclerosis using autologous t cells |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993021222A1 (en) | 1992-04-09 | 1993-10-28 | Autoimmune, Inc. | Suppression of t-cell proliferation using peptide fragments of myelin basic protein |
| US6410518B1 (en) * | 1994-05-31 | 2002-06-25 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide inhibition of raf gene expression |
| US20020042423A1 (en) | 1998-04-29 | 2002-04-11 | John R. Richert | Methods for identifying compounds that bind to hla molecules and use of such compounds as hla-agonists or antagonists |
| EP1407004B1 (en) * | 2001-05-15 | 2009-08-05 | Ortho-McNeil-Janssen Pharmaceuticals, Inc. | Ex-vivo priming for generating cd40-ligand specific cytotoxic t lymphocytes to treat autoimmune and allergic disease |
| US7658926B2 (en) * | 2001-09-14 | 2010-02-09 | Opexa Pharmaceuticals, Inc. | Autologous T-cell vaccines materials and methods |
| IL164376A0 (en) | 2002-04-03 | 2005-12-18 | Applied Research Systems | Ox4or binding agents, their preparation and pharmaceutical compositions containing them |
| EP1677821B1 (en) * | 2003-10-17 | 2013-02-27 | Baylor College Of Medicine | A method for increasing cd8+ cytotoxic t cell reponses and for treating multiple sclerosis |
-
2004
- 2004-10-18 EP EP04795590A patent/EP1677821B1/en not_active Expired - Lifetime
- 2004-10-18 BR BRPI0415519-0A patent/BRPI0415519A/pt not_active Application Discontinuation
- 2004-10-18 NZ NZ546552A patent/NZ546552A/en not_active IP Right Cessation
- 2004-10-18 AU AU2004281817A patent/AU2004281817B2/en not_active Ceased
- 2004-10-18 US US10/575,831 patent/US20080107664A1/en not_active Abandoned
- 2004-10-18 WO PCT/US2004/034448 patent/WO2005037309A1/en not_active Ceased
- 2004-10-18 JP JP2006535420A patent/JP2007509063A/ja active Pending
- 2004-10-18 CA CA2542668A patent/CA2542668C/en not_active Expired - Fee Related
- 2004-10-18 CN CNA2004800372329A patent/CN1893971A/zh active Pending
-
2006
- 2006-04-11 IL IL174935A patent/IL174935A/en not_active IP Right Cessation
-
2009
- 2009-12-03 US US12/630,228 patent/US20100183546A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005535328A5 (enExample) | ||
| Nishimura et al. | Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development | |
| RU2015138483A (ru) | Способы получения из опухоли обогащенных популяций реактивных в отношении опухоли т-клеток | |
| PL351893A1 (en) | Vaccines | |
| RU2005137167A (ru) | Композиции и способы для wt1 специфической иммунотерапии | |
| DK0633929T3 (da) | Fremgangsmåde til in vitro proliferation af dendritcelleforstadier og deres anvendelse til at producere immunogener | |
| CN107254439A (zh) | 增强自然杀伤细胞增殖和活性的方法 | |
| DK1326961T3 (da) | Sammensætninger og fremgangsmåder tl inducering af specifikke cytolytiske T-cellereaktioner | |
| Goldmann et al. | Oral gene application using chitosan-DNA nanoparticles induces transferable tolerance | |
| EP2034009A3 (en) | Compositions and methods for restoring immune responsiveness in patients with immunological defects basing on cd3/cd28 costimulation | |
| ATE389712T1 (de) | Krebs immuntherapie mit semi-allogenen zellen | |
| JP2006519228A5 (ja) | 抗原に対し霊長類を免疫寛容化する抗体の使用法 | |
| Cheever et al. | Tumor neutralization, immunotherapy, and chemoimmunotherapy of a Friend leukemia with cells secondarily sensitized in vitro | |
| Waaga et al. | MECHANISMS OF INDIRECT ALLORECOGNITION: Characterization of MHC Class II Allopeptide-Specific T Helper Cell Clones From Animals Undergoing Acute Allograft Rejection: 1 | |
| US20100183546A1 (en) | Method for Increasing CD8+ Cytotoxic T Cell Responses and for Treating Multiple Sclerosis | |
| Rahbar et al. | Agent-based modeling of tumor and immune system interactions in combinational therapy with low-dose 5-fluorouracil and dendritic cell vaccine in melanoma B16F10 | |
| Reisner et al. | The role of megadose CD34+ progenitor cells in the treatment of leukemia patients without a matched donor and in tolerance induction for organ transplantation | |
| JP2022023136A5 (enExample) | ||
| Kurihara et al. | Potential immunogenicity of adult T cell leukemia cells in vivo | |
| JP2005034154A5 (enExample) | ||
| Hippen et al. | Multiply restimulated human thymic regulatory T cells express distinct signature regulatory T-cell transcription factors without evidence of exhaustion | |
| JP2019508056A5 (enExample) | ||
| Krone et al. | Melanoma, Darwinian medicine and the inner world | |
| NO983917L (no) | Anvendelse av IL-7 for behandling av autoimmune sykdommer og sµrlig insulinavhengig diabetes mellitus | |
| Hamblin | From dendritic cells to tumour vaccines. |